On September 25, GENSCRIPT BIO rose 8.05% in regular trading, trading at 42.58 HKD/share, with turnover of approximately 118 million HKD. The rebound followed the prior session's 3.45% pullback triggered by profit-taking after a sharp rally that had pushed shares above JPMorgan's 41 HKD target price.

On the catalyst front, the company recently partnered with Eli Lilly's AI drug discovery platform Lilly TuneLab to provide wet laboratory services, accelerating the conversion of AI predictions into biological validation data. A leading brokerage noted that AI-driven protein orders are expected to sustain triple-digit percentage growth in the second half and beyond. Additionally, Anthropic recently disclosed breakthroughs by its Claude model in scientific research, further reinforcing the dry-wet experiment closed-loop thesis central to AI-driven drug discovery. The Medical Industry 15th Five-Year Plan, jointly issued by ten government departments, also explicitly supports AI-empowered pharmaceutical R&D, providing further policy tailwinds. Multiple catalysts converged to drive capital back into the stock following the brief correction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)